Versatope utilizes Recombinant Extracellular Transport Vesicles (RET-Vs) to deliver cross-strain immunity against infectious diseases and targeted RNA therapeutics for cancer. This biotechnology platform enables the rapid design and production of effective vaccines that confer long-term immunity and protect against emerging viral strains.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccine technologies often struggle to provide broad protection against rapidly evolving infectious diseases like influenza, requiring frequent reformulation and revaccination. Traditional vaccine development and manufacturing processes can also be slow and inflexible, hindering rapid responses to emerging viral threats and limiting the ability to target specific cancer subtypes with RNA therapeutics.
Solution
Versatope leverages Recombinant Extracellular Transport Vesicles (RET-Vs) to create vaccines and targeted RNA therapies. Their biotechnology platform engineers probiotic-derived vesicles to display multiple antigens, enabling cross-strain immunity against infectious diseases such as influenza and malaria. The RET-Vs can also deliver therapeutic RNA directly into cancer cells, offering a novel approach to immunotherapy. Versatope's platform allows for rapid synthesis, scale-up, and distribution of vaccines and therapeutics, and the resulting products are thermostable, simplifying storage and transport. By displaying multiple viral variants on a single vesicle, Versatope aims to design more effective vaccines that protect against emerging strains and confer long-term immunity.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel vaccines for infectious diseases and targeted RNA therapeutics for cancer.
Features
- Recombinant Extracellular Transport Vesicles (RET-Vs) derived from probiotics
- Display of multiple viral variants on a single vesicle for broad cross-strain immunity
- Targeted delivery of therapeutic RNA directly into cancer cells
- Rapid vaccine synthesis, scale-up, and distribution capabilities
- Thermostable formulations for simplified storage and transport
- Molecular engineering of proprietary cell lines for RET-V production
- Bioinformatics and synthetic biology-driven design process